Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Malaria transmission blocking vaccines - Ehime University/Sumitomo Pharma

Next Previous
Search
Drug Profile

Malaria transmission blocking vaccines - Ehime University/Sumitomo Pharma

Alternative Names: Malaria TBV - Ehime University/Sumitomo Pharma

Latest Information Update: 28 May 2024

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Ehime University; PATH; Sumitomo Dainippon Pharma
  • Developer Ehime University; PATH; Sumitomo Pharma
  • Class Malaria vaccines; Recombinant proteins
  • Mechanism of Action Immunostimulants; Toll-like receptor 7 agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • No development reported Malaria

Most Recent Events

  • 28 May 2024 No recent reports of development identified for research development in Malaria in Japan (Parenteral)
  • 01 Apr 2022 Sumitomo Dainippon Pharma is now called Sumitomo Pharma
  • 03 Apr 2020 Ehime University and Sumitomo Dainippon Pharma receives grant from Global Health Innovative Technology Fund for malaria transmission blocking vaccine development

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top